Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia
Dai Chihara(The University of Texas MD Anderson Cancer Center), Robert J. Kreitman(National Cancer Institute), Constance M. Yuan(National Cancer Institute), Mark Raffeld(National Cancer Institute), Liqiang Xi(Center for Cancer Research), Seth M. Steinberg(National Institutes of Health), Katherine R. Calvo(National Institutes of Health Clinical Center), Wyndham H. Wilson(National Institutes of Health), Julie Feurtado(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Raul C. Braylan(Center for Cancer Research), Evgeny Arons(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), Hong Zhou(National Institutes of Health), Alina Dulau‐Florea(National Institutes of Health), Irina Marić(Center for Cancer Research), Lacey James(National Institutes of Health)
Cited by 104
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k